NICE to Charge up to $282,000 for New Drug Assessments

The UK’s National Institute of Health and Care Excellence (NICE) plans to start charging pharmaceutical companies new fees for each cost-effectiveness assessment for a new medicine beginning next year. The new fees could be up to $282,000! Find out more here. (Source: Zachary Brennan, RAPS, 10/3/16)

You might also be interested in:

CVS Health Execs Respond to NPC’s Criticism of New Program September 18, 2018
FDA to Use 3-Step Approach in RWE Initiative December 7, 2018
Opinions Divided on CVS Program September 19, 2018
CVS Caremark’s Foray into Cost-Effectiveness Analysis… September 25, 2018
ICER Mulls Biopharma Evaluation Program October 17, 2018
ICER Using New Economic Modeling Platform for Value Assessment August 24, 2018
Study: ICER Value Assessments Could Leave Medicare Part B… June 2, 2018